NCCN releases statement addressing ongoing chemotherapy shortages; Shares survey results finding more than 90% of cancer centers are impacted
NCCN calls on Federal Government, pharmaceutical industry, providers, and payers to work together on solutions, as 93% of cancer centers surveyed report a shortage of carboplatin and 70% report shortages for cisplatin
2023-06-07
(Press-News.org) PLYMOUTH MEETING, PA [June 7, 2023] — The National Comprehensive Cancer Network® (NCCN®)—an alliance of leading academic cancer centers—published survey results today that shed light on just how widespread the current platinum chemotherapy shortage is, and shared a statement calling on the whole oncology community to work together on solutions.
“This is an unacceptable situation. We are hearing from oncologists and pharmacists across the country who have to scramble to find appropriate alternatives for treating their patients with cancer right now,” said Robert W. Carlson, MD, Chief Executive Officer, NCCN. “We were relieved by survey results that show patients are still able to get life-saving care, but it comes at a burden to our overtaxed medical facilities. We need to work together to improve the current situation and prevent it from happening again in the future.”
The statement from NCCN’s Policy and Advocacy department outlines specific steps that can be taken by the Federal Government, pharmaceutical industry, providers, and payers to help mitigate any impacts from the anti-cancer drug shortages. It notes: “The causes and solutions to the recurrent anti-cancer drug shortages that deprive oncology patients of optimal therapy are multiple and fixable. Effective solutions require a whole of oncology effort if they are to be successful.”
Carboplatin and cisplatin are platinum-based chemotherapies that are frequently used together for systemic treatment, often with the intent to cure. They have been proven to be highly effective across a variety of cancer types, including lung, breast, and prostate cancers, as well as many leukemias and lymphomas. These two treatments are indicated hundreds of times throughout the NCCN Drugs & Biologics Compendium (NCCN Compendium®)—a searchable database of every recommended medication use found in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). They are estimated to be used in the treatment of as many as 500,000 new cancer patients per year[1].
The survey conducted by the NCCN Best Practices Committee features answers from 27 NCCN Member Institutions serving patients with cancer across the United States. According to their results, 93% of the centers are currently experiencing a shortage of carboplatin, and 70% have a similar lack of cisplatin.
According to the survey, which ran May 23-31, 2023, 100% of the centers are still able to treat patients who need cisplatin without any delays or claim denials. However, for carboplatin, that number drops to only 64% of centers that are able to keep all current carboplatin patients on the regimen. Another 20% report being able to continue this prescription for some but not all patients. Overall, 16% report treatment delays as a result of needing to re-obtain prior-authorization for modified treatment plans, but none have met with outright denials.
“These results demonstrate the widespread impact of the chemotherapy shortage,” said Alyssa Schatz, MSW, Senior Director of Policy and Advocacy for NCCN. “We hope that by sharing this survey and calling for united action across the oncology community, we can come together to prevent future drug shortages and ensure quality, effective, equitable, and accessible cancer care for all.”
The survey revealed that 40% of centers have received information from manufacturers and suppliers on when availability for carboplatin and cisplatin should resume.
Visit NCCN.org/platinum-statement to view the full statement and NCCN.org/platinum-survey for the survey results.
# # #
About the National Comprehensive Cancer Network
The National Comprehensive Cancer Network® (NCCN®) is a not-for-profit alliance of leading cancer centers devoted to patient care, research, and education. NCCN is dedicated to improving and facilitating quality, effective, equitable, and accessible cancer care so all patients can live better lives. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) provide transparent, evidence-based, expert consensus recommendations for cancer treatment, prevention, and supportive services; they are the recognized standard for clinical direction and policy in cancer management and the most thorough and frequently-updated clinical practice guidelines available in any area of medicine. The NCCN Guidelines for Patients® provide expert cancer treatment information to inform and empower patients and caregivers, through support from the NCCN Foundation®. NCCN also advances continuing education, global initiatives, policy, and research collaboration and publication in oncology. Visit NCCN.org for more information.
[1] https://cancerletter.com/conversation-with-the-cancer-letter/20230530_1/
END
ELSE PRESS RELEASES FROM THIS DATE:
2023-06-07
In this project volumetric bioprinting was for the first time successfully combined with melt electrowriting. This combines the speed and cell-friendliness of volumetric printing with the structural strength needed to create functional blood vessels. The study by the biofabrication lab of Regenerative Medicine Center Utrecht (RMCU) was published today in Advanced Materials.
Volumetric printing is a technique that was pioneered for bioprinting by the RMCU biofabrication lab in 2019. It is a fast technique, which allows cells to survive the printing process. However, because this ...
2023-06-07
In just 7 years, the Irish Potato Famine caused approximately one million people to starve to death and forced another estimated million to flee Ireland as refugees. A mold called Phytophthora infestans infected Ireland’s potato crop, a staple food, and spread rapidly throughout the island. The seemingly tiny fungus destroyed roughly 75% of potato crops over the duration of the great hunger. This catastrophic famine, along with several others in various parts of the world throughout history, highlighted the critical need for the study of plant diseases.
Decades ...
2023-06-07
Researchers from University of St. Gallen and Columbia Business School published a new Journal of Marketing article that examines how the perceived meaning of manual labor can help predict the adoption of autonomous products.
The study, forthcoming in the Journal of Marketing, is titled “Meaning of Manual Labor Impedes Consumer Adoption of Autonomous Products” and is authored by Emanuel de Bellis, Gita Venkataramani Johar, and Nicola Poletti.
Whether it is cleaning homes or mowing lawns, consumers increasingly delegate manual tasks to autonomous products. These gadgets operate without human oversight and free consumers from ...
2023-06-07
Reston, Virginia—The SNMMI Mars Shot Research Fund is excited to announce that Paul Ellison, PhD, assistant professor at the Department of Medical Physics at the University of Wisconsin School of Medicine and Public Health in Madison, has been selected as the recipient of a $500,000 grant from the 2023 Mars Shot Fund. The grants recognize individuals who have made transformative impact in the field and elevated the value of nuclear medicine and molecular imaging.
The grant is one of five awarded in the inaugural year of the new SNMMI Mars Shot Research Fund, which ...
2023-06-07
Reston, Virginia—The SNMMI Mars Shot Research Fund is excited to announce that Amir Iravani, MD, associate professor of radiology in the Department of Radiology at the University of Washington School of Medicine in Seattle, Washington, has been selected as the recipient of a $1,000,000 SNMMI Mars Shot Fund Grant. The grants recognize individuals who have made transformative impact in the field and elevated the value of nuclear medicine and molecular imaging.
The grant is one of five awarded in the inaugural year of the new SNMMI Mars Shot Research Fund, which was established to provide resources that translate visionary nuclear medicine imaging, radiopharmaceutical therapy ...
2023-06-07
Reston, Virginia—The SNMMI Mars Shot Research Fund is excited to announce that Craig Levin, PhD, professor of radiology, physics, electrical engineering and bioengineering at Stanford University in Stanford, California, has been selected as the recipient of a $500,000 grant from the 2023 Mars Shot Fund. The grants recognize individuals who have made transformative impact in the field and elevated the value of nuclear medicine and molecular imaging.
The grant is one of five awarded in the inaugural year of the new SNMMI Mars Shot Research Fund, which was established to provide ...
2023-06-07
Reston, Virginia—The SNMMI Mars Shot Research Fund is excited to announce that Julie Sutcliffe, PhD, professor of internal medicine and biomedical engineering, University of California–Davis, has been selected as the recipient of a $500,000 grant from the 2023 Mars Shot Fund. The grants recognize individuals who have made transformative impact in the field and elevated the value of nuclear medicine and molecular imaging.
The grant is one of five awarded in the inaugural year of the new SNMMI Mars Shot Research Fund, which was established to provide ...
2023-06-07
Reston, Virginia—The SNMMI Mars Shot Research Fund is excited to announce that Randy Yeh, MD, a radiologist and nuclear medicine physician at Memorial Sloan Kettering Cancer Center and assistant professor of radiology at Weill Cornell Medical College in New York, has been selected as the recipient of a $500,000 grant from the 2023 Mars Shot Fund. The grants recognize individuals who have made transformative impact in the field and elevated the value of nuclear medicine and molecular imaging.
The grant is one of five awarded in the inaugural year of the new SNMMI Mars Shot Research Fund, which ...
2023-06-07
KANSAS CITY, MO—June 7, 2023—The placenta, critical for healthy embryo development, is a multi- purpose organ with a precise lifespan—the length of a pregnancy. New research from the Stowers Institute for Medical Research suggests that further exploration of the placenta’s roles and capabilities may one day lead to insights for positive pregnancy outcomes.
The study published in Development on June 6, 2023, focuses on a unique property of many cells comprising the placenta that explains how these cells perform essential functional and physical ...
2023-06-07
More than 5,000 people are diagnosed annually with ALS (amyotrophic lateral sclerosis), a fatal, neurodegenerative disease that attacks nerve cells in the brain and spinal cord, gradually robbing people of the ability to speak, move, eat and breathe.
To date, only a handful of drugs exist to moderately slow its progression. There is no cure.
But CU Boulder researchers have identified a surprising new player in the disease—an ancient, virus-like protein best known, paradoxically, for its essential role in enabling placental development.
The findings ...
LAST 30 PRESS RELEASES:
[Press-News.org] NCCN releases statement addressing ongoing chemotherapy shortages; Shares survey results finding more than 90% of cancer centers are impacted
NCCN calls on Federal Government, pharmaceutical industry, providers, and payers to work together on solutions, as 93% of cancer centers surveyed report a shortage of carboplatin and 70% report shortages for cisplatin
